KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Current Assets (2016 - 2025)

NovoCure's Current Assets history spans 12 years, with the latest figure at $646.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 41.56% year-over-year to $646.7 million; the TTM value through Dec 2025 reached $646.7 million, down 41.56%, while the annual FY2025 figure was $646.7 million, 41.56% down from the prior year.
  • Current Assets for Q4 2025 was $646.7 million at NovoCure, down from $1.2 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.2 billion in Q3 2025 and bottomed at $646.7 million in Q4 2025.
  • The 5-year median for Current Assets is $1.1 billion (2022), against an average of $1.1 billion.
  • The largest annual shift saw Current Assets soared 178.76% in 2021 before it tumbled 41.56% in 2025.
  • A 5-year view of Current Assets shows it stood at $1.1 billion in 2021, then increased by 3.54% to $1.1 billion in 2022, then dropped by 6.94% to $1.0 billion in 2023, then grew by 6.98% to $1.1 billion in 2024, then crashed by 41.56% to $646.7 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Current Assets are $646.7 million (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).